• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Severe Soft Tissue Soft Tissue Necrosis Topical Cool Drug Monograph Extravasation Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Levin M, Caravone D, Geiser C: Mitoxantrone extravasation and tissue necrosis. Am J Health-Syst Pharm 53: 1192–1194, 1996.PubMedGoogle Scholar
  2. [2]
    Peters FT, Beijnen JH, Huinink WW: Mitoxantrone extravasation injury. Cancer Treat Rep 71: 992–993 1987.PubMedGoogle Scholar
  3. [3]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  4. [4]
    Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.PubMedCrossRefGoogle Scholar
  5. [5]
    Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.Google Scholar
  6. [6]
    Kara M, Ross DC: Severe soft tissue necrosis after extravasation of mitoxantrone: case report. Can J Plast Surg 6: 204–206, 1998.Google Scholar
  7. [7] Von Hoff DD, Pollard E, Kuhn J, et al: Phase I clinical investigation of 1,4dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl)amino]
    ethyl} amino}}-9, 10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40: 1516–1518, 1980.Google Scholar
  8. [8]
    Alberts DS, Griffith KS, Goodman GE, et al: Phase I clinical trial of mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother Pharmacol 5: 11–15, 1980.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [9]
    Posner LE, Dukart G, Goldberg J, et al: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3: 123–132, 1985.PubMedCrossRefGoogle Scholar
  2. [10]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  3. [11]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  4. [12]
    Gain M, Melzer S, Meyer-Jaishof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  5. [13]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  6. [14]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  7. [15]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  8. [16]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  9. [17]
    Dorr RT, Von Hoff DD: Drug monographs: mitoxantrone hydrochloride. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 730–735, 1994.Google Scholar
  10. [18]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  11. [19]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar

Further reading

  1. [—]
    Dorr RT, Alberts DS, Soble M: Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 16: 91–94, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations